Protein kinase Cδ and c-Abl kinase are required for transforming growth factor β induction of endothelial-mesenchymal transition in vitro

Arthritis and Rheumatism

Volumn 63, Issue 8, 2011, Pages 2473-2483

  Li, Zhaodong ^a   Jimenez, Sergio A ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ABELSON KINASE; ALPHA SMOOTH MUSCLE ACTIN; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CD34 ANTIBODY; COLLAGEN TYPE 1; GLYCOGEN SYNTHASE KINASE 3BETA; IMATINIB; INTERCELLULAR ADHESION MOLECULE 2; LOW DENSITY LIPOPROTEIN; PROTEIN KINASE C DELTA; ROTTLERIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR SNAIL; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; VASCULAR ENDOTHELIAL CADHERIN;

ANIMAL CELL; ARTICLE; CELL STRUCTURE; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM CELL; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; EPITHELIAL MESENCHYMAL TRANSITION; IMMUNOMAGNETIC SEPARATION; IN VITRO STUDY; MOUSE; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANIMALS; CELL TRANSDIFFERENTIATION; CELLS, CULTURED; ENDOTHELIAL CELLS; MICE; MYOFIBROBLASTS; PROTEIN KINASE C-DELTA; PROTO-ONCOGENE PROTEINS C-ABL; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 79961120675     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30317     Document Type: Article

References (41)

1. Avery RK,. Cardiac-allograft vasculopathy. N Engl J Med 2003; 349: 829-30. (Pubitemid 37025401)
2. Pietra GG, Capron F, Stewart S, Leone O, Humbert M, Robbins IM, et al. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 2004; 43: 25-32S.
3. Fleming JN, Nash RA, Mahoney WM Jr, Schwartz SM,. Is scleroderma a vasculopathy? Curr Rheumatol Rep 2009; 11: 103-10.
4. Kahaleh MB, LeRoy EC,. Autoimmunity and vascular involvement in systemic sclerosis (SSc). Autoimmunity 1999; 31: 195-214. (Pubitemid 30179202)
5. Arciniegas E, Neves CY, Carrillo LM, Zambrano EA, Ramirez R,. Endothelial-mesenchymal transition occurs during embryonic pulmonary artery development. Endothelium 2005; 12: 193-200. (Pubitemid 41600864)
6. Chaudhuri V, Zhou L, Karasek M,. Inflammatory cytokines induce the transformation of human dermal microvascular endothelial cells into myofibroblasts: a potential role in skin fibrogenesis. J Cutan Pathol 2007; 34: 146-53. (Pubitemid 46145554)
7. Arciniegas E, Frid MG, Douglas IS, Stenmark KR,. Perspectives on endothelial-to-mesenchymal transition: potential contribution to vascular remodeling in chronic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2007; 293: L1-8. (Pubitemid 47080705)
8. Zeisberg EM, Tarnavski O, Zeisberg M, Dorfman AL, McMullen JR, Gustafsson E, et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med 2007; 13: 952-61. (Pubitemid 47222040)
9. Zeisberg EM, Potenta SE, Sugimoto H, Zeisberg M, Kalluri R,. Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J Am Soc Nephrol 2008; 19: 2282-7.
10. Kizu A, Medici D, Kalluri R,. Endothelial-mesenchymal transition as a novel mechanism for generating myofibroblasts during diabetic nephropathy. Am J Pathol 2009; 175: 1371-3.
11. Hashimoto N, Phan SH, Imaizumi K, Matsuo M, Nakashima H, Kawabe T, et al. Endothelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 2010; 43: 161-72.
12. Li J, Qu X, Bertram JF,. Endothelial-myofibroblast transition contributes to the early development of diabetic renal interstitial fibrosis in streptozotocin-induced diabetic mice. Am J Pathol 2009; 175: 1380-8.
13. Goumans MJ, van Zonneveld AJ, ten Dijke P,. Transforming growth factor β-induced endothelial-to-mesenchymal transition: a switch to cardiac fibrosis? Trends Cardiovasc Med 2008; 18: 293-8.
14. Branton MH, Kopp JB,. TGF-β and fibrosis. Microbes Infect 1999; 1: 1349-65.
15. Prud'homme GJ,. Pathobiology of transforming growth factor β in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab Invest 2007; 87: 1077-91.
16. Rosenbloom J, Castro SV, Jimenez SA,. Narrative review: fibrotic diseases: cellular and molecular mechanisms and novel therapies. Ann Intern Med 2010; 152: 159-66.
17. Varga J, Whitfield ML,. Transforming growth factor-β in systemic sclerosis (scleroderma). Front Biosci 2009; 1: 226-35.
18. Vincent T, Neve EP, Johnson JR, Kukalev A, Rojo F, Albanell J, et al. A SNAIL-1-SMAD3/4 transcriptional repressor complex promotes TGF-β mediated epithelial-mesenchymal transition. Nat Cell Biol 2009; 11: 943-50.
19. Zavadil J, Bottinger EP,. TGF-β and epithelial-to-mesenchymal transitions. Oncogene 2005; 24: 5764-74.
20. Xu J, Lamouille S, Derynck R,. TGF-β-induced epithelial to mesenchymal transition. Cell Res 2009; 19: 156-72.
21. Zeisberg M, Hanai J, Sugimoto H, Mammoto T, Charytan D, Strutz F, et al. BMP-7 counteracts TGF-β1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 2003: 9: 964-8. (Pubitemid 36889942)
22. Marelli-Berg FM, Peek E, Lidington EA, Stauss HJ, Lechler RI,. Isolation of endothelial cells from murine tissue. J Immunol Methods 2000; 244: 205-15.
23. Larrivee B, Karsan A,. Isolation and culture of primary endothelial cells. Methods Mol Biol 2005; 290: 315-29.
24. Voyta JC, Via DP, Butterfield CE, Zetter BR,. Identification and isolation of endothelial cells based on their increased uptake of acetylated-low density lipoprotein. J Cell Biol 1984; 99: 2034-40. (Pubitemid 15181864)
25. Savagner P, Yamada KM, Thiery JP,. The zinc-finger protein slug causes desmosome dissociation, an initial and necessary step for growth factor-induced epithelial-mesenchymal transition. J Cell Biol 1997; 137: 1403-19. (Pubitemid 27265951)
26. Barrallo-Gimeno A, Nieto MA,. The Snail genes as inducers of cell movement and survival: implications in development and cancer. Development 2005; 132: 3151-61. (Pubitemid 41167144)
27. Nieto MA,. Epithelial-Mesenchymal Transitions in development and disease: old views and new perspectives. Int J Dev Biol 2009; 53: 1541-7.
28. Zhou BP, Deng J, Xia W, Xu J, Li YM, Gunduz M, et al. Dual regulation of Snail by GSK-3β-mediated phosphorylation in control of epithelial- mesenchymal transition. Nat Cell Biol 2004; 6: 931-40. (Pubitemid 39359846)
29. Doble BW, Woodgett JR,. Role of glycogen synthase kinase-3 in cell fate and epithelial-mesenchymal transitions. Cells Tissues Organs 2007; 185: 73-84. (Pubitemid 46956846)
30. Peinado H, Portillo F, Cano A,. Switching on-off Snail: LOXL2 versus GSK3β. Cell Cycle 2005; 4: 1749-52. (Pubitemid 41827319)
31. Batlle E, Sancho E, Franci C, Dominguez D, Monfar M, Baulida J, et al. The transcription factor Snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol 2000; 2: 84-9.
32. Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, et al. The transcription factor Snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2000; 2: 76-83.
33. Kokudo T, Suzuki Y, Yoshimatsu Y, Yamazaki T, Watabe T, Miyazono K,. Snail is required for TGFβ-induced endothelial-mesenchymal transition of embryonic stem cell-derived endothelial cells. J Cell Sci 2008; 121: 3317-24.
34. Daniels CE, Wilkes MC, Edens M, Kottom TJ, Murphy SJ, Limper AH, et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-β and prevents bleomycin-mediated lung fibrosis. J Clin Invest 2004; 114: 1308-16. (Pubitemid 40385302)
35. Bibi Y, Gottlieb AB,. A potential role for imatinib and other small molecule tyrosine kinase inhibitors in the treatment of systemic and localized sclerosis. J Am Acad Dermatol 2008; 59: 654-8.
36. Distler JH, Distler O,. Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies. Ann Rheum Dis 2010; 69 Suppl I: i48-51.
37. Distler JH, Jungel A, Huber LC, Schulze-Horsel U, Zwerina J, Gay RE, et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007; 56: 311-22. (Pubitemid 46106205)
38. Akhmetshina A, Venalis P, Dees C, Busch N, Zwerina J, Schett G, et al. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum 2009; 60: 219-24.
39. Aono Y, Nishioka Y, Inayama M, Ugai M, Kishi J, Uehara H, et al. Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Crit Care Med 2005; 171: 1279-85. (Pubitemid 40740736)
40. Jimenez SA, Gaidarova S, Saitta B, Sandorfi N, Herrich DJ, Rosenbloom JC, et al. Role of protein kinase C-δ in the regulation of collagen gene expression in scleroderma fibroblasts. J Clin Invest 2001; 108: 1395-403. (Pubitemid 33107768)
41. Gore-Hyer E, Pannu J, Smith EA, Grotendorst G, Trojanowska M,. Selective stimulation of collagen synthesis in the presence of costimulatory insulin signaling by connective tissue growth factor in scleroderma fibroblasts. Arthritis Rheum 2003; 48: 798-806. (Pubitemid 36302018)